November 15, 2006 – Pfizer bought an ag-biotech company called Embrex for $17 per share or a total of $155 million; Pfizer also announced that high doses of Lipitor reduced the incidence of major cardiovascular events by 32%; StemCells made the first transplantation of its human neural stem cell product in a Phase I trial; Emergent BioSolutions priced its IPO at $12.50 per share but dropped in open market trading; Trimeris will focus on making its HIV drug Fuzeon profitable; and Immunomedics said the clinical hold on its lupus drug has been lifted. The Centient Biotech 200™ rose 16 points to 3971, an increase of .40%. More details...
